Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment‑naïve patients.
Saved in:
| Title: | Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment‑naïve patients. |
|---|---|
| Authors: | Murata T; Department of Ophthalmology, Shinshu University School of Medicine, 3‑1‑1 Asahi, Matsumoto, Nagano, Japan. murata@shinshu-u.ac.jp., Kondo M; Department of Ophthalmology, Mie University Graduate School of Medicine, Mie, Japan., Inoue M; Department of Ophthalmology, Kyorin Eye Center, Kyorin University School of Medicine, Tokyo, Japan., Nakao S; Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Osaka R; Department of Ophthalmology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Shiragami C; Department of Ophthalmology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Sogawa K; Department of Ophthalmology, Asahikawa Medical University, Hokkaido, Japan., Mochizuki A; Novartis Pharma K.K., Tokyo, Japan., Shiraga R; Novartis Pharma K.K., Tokyo, Japan., Ohashi Y; Novartis Pharma K.K., Tokyo, Japan., Kaneko T; Novartis Pharma K.K., Tokyo, Japan., Chandrasekhar C; Novartis Healthcare Pvt. Ltd., Hyderabad, India., Tsujikawa A; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan., Kamei M; Department of Ophthalmology, Aichi Medical University, Aichi, Japan. |
| Source: | Scientific reports [Sci Rep] 2021 Jul 07; Vol. 11 (1), pp. 14400. Date of Electronic Publication: 2021 Jul 07. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
